Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review.

ABSTRACT:

Objectives

This study undertook a scoping review of research on blood fibroblast growth factor 23 (FGF-23) concentrations in healthy non-azotemic cats and cats with chronic kidney disease (CKD) to describe the volume and nature of existing literature, to determine whether published studies provide adequate evidence to support the use of FGF-23 as a biomarker in clinical practice and to identify any existing gaps in knowledge.

Methods

PRISMA Extension for Scoping Reviews guidelines were used to design and perform the scoping review. Online databases were used to identify observational and clinical studies of blood FGF-23 concentrations in healthy cats and cats with CKD published before December 2022. Study and population characteristics and descriptive data on FGF-23 concentr

SUBMITTER: Summers S 

PROVIDER: S-EPMC11103316 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature